CAR T-cell Therapy | Specialty

FDA Approval for Axi-Cel in NHL

January 9th 2018

Need for Salvage Therapies in R/R NHL

January 9th 2018

Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

Mechanisms of Resistance for CAR T Therapy

January 9th 2018

Managing CAR T-Cell Therapy Toxicity

January 9th 2018

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018

Dr. Brentjens on Research Beyond CD19 in CAR T-Cell Therapy

January 5th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for CAR T-cell therapy.

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

January 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.

Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL

December 29th 2017

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).

Dr. Maloney on CAR T-Cell Product in B-Cell Lymphoma

December 19th 2017

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the preliminary safety data of the chimeric antigen receptor (CAR) T-cell product, JCAR017, in relapsed/refractory aggressive B-cell lymphoma.

Cellular Immunotherapy Expert Explains CAR T-Cell Therapy Excitement

December 16th 2017

Marcela V. Maus, MD, PhD, evaluates the next generation of chimeric antigen receptor (CAR) T cells in both hematologic malignancies and solid tumors

Prime Time for CAR T Cells

December 15th 2017

Chimeric antigen receptor (CAR) T cells have hit prime time, with the 2 recent FDA approvals for this class of cell-based therapy.

Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

December 14th 2017

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

December 12th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL

December 12th 2017

Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Tisagenlecleucel Continues to Impress in DLBCL

December 10th 2017

The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.